Brought to you by 
Bayer, CRISPR form gene editing JV to cure blood disorders, blindness, and congenital heart disease
23 Oct 2019
Executive Summary
Bayer HealthCare Pharmaceuticals AG and CRISPR Therapeutics formed a 50/50 joint venture tasked with finding cures for blood disorders (including hemophilia), blindness, and congenital heart disease. The Bayer LifeScience Center (BLSC), a new R&D innovation unit at Bayer, help set up the JV, which will focus on creating delivery systems for systemic administration of CRISPR-Cas9 technology.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Joint Venture
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer, CRISPR form gene editing JV to cure blood disorders, blindness, and congenital heart disease
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice